PMID- 28274154
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20220408
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 26
IP  - 4
DP  - 2017 Apr
TI  - Investigational drugs for the treatment of cervical cancer.
PG  - 389-402
LID - 10.1080/13543784.2017.1302427 [doi]
AB  - Cervical cancer (CC) is currently the fourth most common malignant disease of 
      women worldwide. Although the incidence and the mortality rates have been 
      decreasing with screening detection and new treatment strategies, a significant 
      number of metastatic or recurrent disease is still diagnosed. For those patients 
      not amenable to curative treatments, such as surgery and radiation, palliative 
      chemotherapy remains the standard of care. As chemotherapy regimens have limited 
      activity, research is focalized on investigating novel pharmacologic strategies. 
      Areas covered: This paper aims to give a complete and updated overview on 
      investigated therapies for the treatment of CC. The authors review the results of 
      clinical studies and highlight the ongoing trials. Expert opinion: Agents 
      targeting various molecular pathways including epidermal growth factor receptor 
      (EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin 
      (mTOR), poly ADP-ribose polymerase (PARP), epigenetics and other biological 
      mechanisms represent interesting investigational opportunities. Amongst such 
      drugs, bevacizumab, an anti-VEGF monoclonal antibody, was the first targeted drug 
      recently approved by the FDA for the treatment of patients with metastatic, 
      recurrent, or persistent CC. Another interesting experimental approach is 
      represented by immunotherapy, which is leading to promising results with to the 
      development of therapeutic vaccines and immune checkpoints inhibitors.
FAU - Barra, Fabio
AU  - Barra F
AD  - a Academic Unit of Obstetrics and Gynecology , IRCCS AOU San Martino - IST , 
      Genoa , Italy.
AD  - b Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal 
      and Child Health (DiNOGMI) , University of Genoa , Genoa , Italy.
FAU - Lorusso, Domenica
AU  - Lorusso D
AD  - c Department of Gynecologic Oncology , IRCCS National Cancer Institute , Milan , 
      Italy.
FAU - Leone Roberti Maggiore, Umberto
AU  - Leone Roberti Maggiore U
AD  - a Academic Unit of Obstetrics and Gynecology , IRCCS AOU San Martino - IST , 
      Genoa , Italy.
AD  - b Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal 
      and Child Health (DiNOGMI) , University of Genoa , Genoa , Italy.
FAU - Ditto, Antonino
AU  - Ditto A
AD  - c Department of Gynecologic Oncology , IRCCS National Cancer Institute , Milan , 
      Italy.
FAU - Bogani, Giorgio
AU  - Bogani G
AD  - c Department of Gynecologic Oncology , IRCCS National Cancer Institute , Milan , 
      Italy.
FAU - Raspagliesi, Francesco
AU  - Raspagliesi F
AD  - c Department of Gynecologic Oncology , IRCCS National Cancer Institute , Milan , 
      Italy.
FAU - Ferrero, Simone
AU  - Ferrero S
AD  - a Academic Unit of Obstetrics and Gynecology , IRCCS AOU San Martino - IST , 
      Genoa , Italy.
AD  - b Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal 
      and Child Health (DiNOGMI) , University of Genoa , Genoa , Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170308
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drugs, Investigational)
SB  - IM
MH  - Angiogenesis Inhibitors/pharmacology
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Drug Design
MH  - Drugs, Investigational/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunotherapy/methods
MH  - Molecular Targeted Therapy
MH  - Uterine Cervical Neoplasms/*drug therapy/pathology
OTO - NOTNLM
OT  - Angiogenesis inhibitors
OT  - cervical cancer
OT  - immunotherapy
OT  - investigational drugs
OT  - targeted therapy
EDAT- 2017/03/10 06:00
MHDA- 2017/04/05 06:00
CRDT- 2017/03/10 06:00
PHST- 2017/03/10 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
PHST- 2017/03/10 06:00 [entrez]
AID - 10.1080/13543784.2017.1302427 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2017 Apr;26(4):389-402. doi: 
      10.1080/13543784.2017.1302427. Epub 2017 Mar 8.